SCORED Trial: Sotagliflozin Showed Robust MACE Benefit SCORED Trial: Sotagliflozin Showed Robust MACE Benefit

Trial results for the ' twincretin ' in patients with diabetes, CKD, and high CVD risk showed robust benefits across MACE outcomes, distinguishing sotagliflozin from the SGLT2 inhibitors.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news